Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00061750 · ClinicalTrials.gov registry record · Phase 3
Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 595
- Enrollment target
NCT00061750 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 595 participants.
The verdict
NCT00061750, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 595 participants
- Enrollment target
Study Summary
The purpose of this study is to deterimine if the new orally active iron chelator, ICL670, is as effective and as safe as deferoxamine in preventing accumulation of iron in the body while a patient is undergoing repeated blood transfusions.
Interventions
- DRUG ICL670
- DRUG deferoxamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 595 participants |
| Start Date | 2003-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00061750
The ClinicalTrials.gov registry entry for NCT00061750 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 595 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ICL670 is the first listed.
NCT00061750 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00061750 about?
NCT00061750 is a clinical study titled "Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions". The purpose of this study is to deterimine if the new orally active iron chelator, ICL670, is as effective and as safe as deferoxamine in preventing accumulation of iron in the body while a patient is undergoing repeated blood transfusions.
What is the current status of trial NCT00061750?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 595 participants. The study started on 2003-05.
What interventions are being tested in trial NCT00061750?
The interventions under investigation include: ICL670 (DRUG), deferoxamine (DRUG).
Who is sponsoring clinical trial NCT00061750?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.